Question

In: Accounting

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April.

2018

  1. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees.
  2. On October 1, borrowed $16 million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 12% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.
  3. Received $3,500 of refundable deposits in December for reusable containers used to transport and store chemical-based products.
  4. For the September–December period, sales on account totaled $4,140,000. The state sales tax rate is 3% and the local sales tax rate is 3%. (This is a summary journal entry for the many individual sales transactions for the period.)
  5. Recorded the adjusting entry for accrued interest.


2019

  1. In February, issued $12.4 million of 10-year bonds at face value and paid the bank loan on the March 1 due date.
  2. Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months.


Required:
1. Prepare the appropriate journal entries for 2018 and 2019 transactions.

Solutions

Expert Solution

Calculation of the rate of sales tax      
Total Sales Tax Rate              
Sales Tax Rate (State)+Sales tax rate(Local)      
3%+3%                  
$3,500       6%                  
Sales Tax                  
Accounts Receivable *Rate of Tax          
$4140000*6%              
$248,400                  
Computation of Accounts Receivable      
Sales Revenue+Sales Tax Payable          
$4140000+$248400              
$4,388,400                  
Computation of Accrued Interest          
Interest Accrued              
Notes payable *Rate of Interest*Number of Months/12
$16000000*12%*3/12              
$480,000                  
Computation of interest Expense          
Interest Expense              
Notes Payable *Rate of Interest *Number of Months/12
$16000000*12%*2/12              
$320,000                  
Computation of cash to be piad          
Interest Expense +Interest Payable+Notes Payable  
$320000+$480000+$16000000          
$16,800,000                  
Computation of the amount of refundable deposits paid
Refundable Deposits paid          
Total Refundable Deposits*1/2          
$3500/2                  
$1,750                  
1   No Journal Entry will be passed for the negotiation of short term LOC.                  
Journal Entry                      
2   Date   Account Title   Dr Amount   Cr Amount              
1st Oct 2018   Cash   $16,000,000                  
To Note Payable       $16,000,000              
to record the issunace of               Calculation of the rate of sales tax
promissory note               Total Sales Tax Rate  
Sales Tax Rate (State)+Sales tax rate(Local)
3       Cash   $3,500           3%+3%      
To Refundable Deposits       $3,500       6%      
to record the receipt of               Sales Tax      
refundable deposits               Accounts Receivable *Rate of Tax
$4140000*6%  
4       Accounts Receivable   $4,388,400           $248,400      
To Sales Revenue       $4,140,000              
To Sales Tax Payable       $248,400       Computation of Accounts Receivable
to record the sales and sales           Sales Revenue+Sales Tax Payable
tax for sep-dec               $4140000+$248400  
$4,388,400      
5       Interest Expense   $480,000                  
To Interest Payable       $480,000       Computation of Accrued Interest
to record the interest               Interest Accrued  
Accrued               Notes payable *Rate of Interest*Number of Months/12
$16000000*12%*3/12  
6       Cash   $12,400,000           $480,000      
To Bonds Payable       $12,400,000              
to record the issue of                      
bonds                      
7   1st March 2019   Interest Expense   $320,000           Computation of interest Expense
Interest Payable   $480,000           Interest Expense  
Notes Payable   $16,000,000           Notes Payable *Rate of Interest *Number of Months/12
To cash       $16,800,000       $16000000*12%*2/12  
to record the repayment               $320,000      
of bank loan along with               Computation of cash to be piad
interest               Interest Expense +Interest Payable+Notes Payable
$320000+$480000+$16000000
Refundable Deposits   $1,750           $16,800,000      
To Cash       $1,750              
To record the payment of                      
Refundable Deposits               Computation of the amount of refundable deposits paid
Refundable Deposits paid
Total Refundable Deposits*1/2
$3500/2      
$1,750      
2       Balance Sheet as at 31st Dec 2018                  
Liabilities   Amount                  
Long Term Liabilities                          
`              
Current Liabilities                          
a   Loan from Second Commercial Bank   $16,000,000                      
c   Security Deposits   $3,500                      
d   Sales Tax Payable   $248,400                      
e   Accrued Interest on loan payable   $480,000                      
f Trade Accounts Payable   $347,000                      
$17,078,900

g storage continers covered $347,000


Related Solutions

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $15,000,000 at the bank's prime rate (10.5% at the time). The company will pay no commitment fees. On October 1, borrowed $12...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $23,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $20...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $8,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $5...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the company for September 2016 through March 2017. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2016 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $29,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $25,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $22...
Grossman Products began operations in 2018. The following selected transactions occurred from September 2018 through March...
Grossman Products began operations in 2018. The following selected transactions occurred from September 2018 through March 2019. Grossman's fiscal year ends on December 31. 2018: (a.) On September 5, Grossman opened a checking account and negotiated a short-term line of credit of up to $10,500,000 at 10% interest. The company is not required to pay any commitment fees. (b.) On October 1, Grossman borrowed $8,500,000 cash and issued a 5-month promissory note with 8% interest payable at maturity. (c.) Grossman...
The following selected transactions relate to liabilities of Interstate Farm Implements for December of 2018. Interstate’s...
The following selected transactions relate to liabilities of Interstate Farm Implements for December of 2018. Interstate’s fiscal year ends on December 31. Required: Prepare the appropriate journal entries for these transactions. 1. On December 15, received $7,500 from Bradley Farms toward the purchase of a $98,000 tractor to be delivered on January 6, 2019. 2. During December, received $25,500 of refundable deposits relating to containers used to transport equipment parts. 3. During December, credit sales totaled $800,000. The state sales...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July 2021. Eastern's fiscal year ends on December 31. Financial statements are published in April 2022. No customer accounts have been shown to be uncollectible as yet, but Eastern estimates that 3% of credit sales will eventually prove uncollectible. Sales were $300 million (all credit) for 2021. Eastern offers a one-year warranty against manufacturer's defects for all its products. Industry experience indicates that warranty costs...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 3% of sales. Sales were $2.3 million (all credit) for 2021. Actual warranty expenditures were $20,100 and were recorded as warranty expense when incurred. Although no customer accounts have...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT